Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.
2.

Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.

Bobrov E, Skobeleva N, Restifo D, Beglyarova N, Cai KQ, Handorf E, Campbell K, Proia DA, Khazak V, Golemis EA, Astsaturov I.

Oncotarget. 2017 Jan 17;8(3):4399-4409. doi: 10.18632/oncotarget.12642.

3.

Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.

Beglyarova N, Banina E, Zhou Y, Mukhamadeeva R, Andrianov G, Bobrov E, Lysenko E, Skobeleva N, Gabitova L, Restifo D, Pressman M, Serebriiskii IG, Hoffman JP, Paz K, Behrens D, Khazak V, Jablonski SA, Golemis EA, Weiner LM, Astsaturov I.

Clin Cancer Res. 2016 Dec 15;22(24):6153-6163. Epub 2016 Jul 6.

4.

A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.

Gaponova AV, Nikonova AS, Deneka A, Kopp MC, Kudinov AE, Skobeleva N, Khazak V, Ogawa LS, Cai KQ, Duncan KE, Duncan JS, Egleston BL, Proia DA, Boumber Y, Golemis EA.

Clin Cancer Res. 2016 Oct 15;22(20):5120-5129. doi: 10.1158/1078-0432.CCR-15-3068. Epub 2016 Jun 7.

5.

HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.

Proia DA, Smith DL, Zhang J, Jimenez JP, Sang J, Ogawa LS, Sequeira M, Acquaviva J, He S, Zhang C, Khazak V, Astsaturov I, Inoue T, Tatsuta N, Osman S, Bates RC, Chimmanamada D, Ying W.

Mol Cancer Ther. 2015 Nov;14(11):2422-32. doi: 10.1158/1535-7163.MCT-15-0455. Epub 2015 Aug 13.

6.

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.

Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23.

7.

A two-hybrid approach to identify inhibitors of the RAS-RAF interaction.

Khazak V, Eyrisch S, Kato J, Tamanoi F, Golemis EA.

Enzymes. 2013;33 Pt A:213-48. doi: 10.1016/B978-0-12-416749-0.00010-5. Epub 2013 Aug 8. Review.

PMID:
25033807
8.

Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells.

González-Pérez V, Reiner DJ, Alan JK, Mitchell C, Edwards LJ, Khazak V, Der CJ, Cox AD.

J Mol Signal. 2010 Feb 23;5:2. doi: 10.1186/1750-2187-5-2.

9.

Isoquinolin-1-one inhibitors of the MDM2-p53 interaction.

Rothweiler U, Czarna A, Krajewski M, Ciombor J, Kalinski C, Khazak V, Ross G, Skobeleva N, Weber L, Holak TA.

ChemMedChem. 2008 Jul;3(7):1118-28. doi: 10.1002/cmdc.200800025.

PMID:
18428185
10.

Ras-driven transformation of human nestin-positive pancreatic epithelial cells.

Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, Der CJ.

Methods Enzymol. 2008;439:451-65. doi: 10.1016/S0076-6879(07)00431-4.

PMID:
18374182
11.

Selective Raf inhibition in cancer therapy.

Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA.

Expert Opin Ther Targets. 2007 Dec;11(12):1587-609. Review. Erratum in: Expert Opin Ther Targets. 2009 Sep;13(9):1135.

12.

Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.

Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, Shields JM.

Mol Cancer Ther. 2007 Aug;6(8):2220-9.

13.
14.

K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.

Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ.

Cancer Res. 2007 Mar 1;67(5):2098-106.

15.

Yeast screens for inhibitors of Ras-Raf interaction and characterization of MCP inhibitors of Ras-Raf interaction.

Khazak V, Kato-Stankiewicz J, Tamanoi F, Golemis EA.

Methods Enzymol. 2006;407:612-29.

PMID:
16757356
16.

Development of a yeast two-hybrid screen for selection of human Ras-Raf protein interaction inhibitors.

Khazak V, Golemis EA, Weber L.

Methods Mol Biol. 2005;310:253-71.

PMID:
16353379
17.

Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.

Lu Y, Sakamuri S, Chen QZ, Keng YF, Khazak V, Illgen K, Schabbert S, Weber L, Menon SR.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):3957-62.

PMID:
15225706
18.

Detection of peptides, proteins, and drugs that selectively interact with protein targets.

Serebriiskii IG, Mitina O, Pugacheva EN, Benevolenskaya E, Kotova E, Toby GG, Khazak V, Kaelin WG, Chernoff J, Golemis EA.

Genome Res. 2002 Nov;12(11):1785-91.

19.

Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells.

Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, Golemis EA, Tamanoi F, Khazak V.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14398-403. Epub 2002 Oct 21.

20.

Redefinition of the yeast two-hybrid system in dialogue with changing priorities in biological research.

Serebriiskii IG, Khazak V, Golemis EA.

Biotechniques. 2001 Mar;30(3):634-6, 638, 640 passim. Review.

21.

Ligand-free RAR can interact with the RNA polymerase II subunit hsRPB7 and repress transcription.

Shen XQ, Bubulya A, Zhou XF, Khazak V, Golemis EA, Shemshedini L.

Endocrine. 1999 Jun;10(3):281-9.

PMID:
10484292
22.

A two-hybrid dual bait system to discriminate specificity of protein interactions.

Serebriiskii I, Khazak V, Golemis EA.

J Biol Chem. 1999 Jun 11;274(24):17080-7.

23.

Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II.

Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H.

Oncogene. 1998 Aug 6;17(5):603-10.

24.

Analysis of the interaction of the novel RNA polymerase II (pol II) subunit hsRPB4 with its partner hsRPB7 and with pol II.

Khazak V, Estojak J, Cho H, Majors J, Sonoda G, Testa JR, Golemis EA.

Mol Cell Biol. 1998 Apr;18(4):1935-45.

25.

Interactions between the human RNA polymerase II subunits.

Acker J, de Graaff M, Cheynel I, Khazak V, Kedinger C, Vigneron M.

J Biol Chem. 1997 Jul 4;272(27):16815-21.

26.

Alternative yeast two-hybrid systems. The interaction trap and interaction mating.

Golemis EA, Khazak V.

Methods Mol Biol. 1997;63:197-218. No abstract available.

PMID:
9113651
27.

Identical amino acid sequence of the aroA(G) gene products of Bacillus subtilis 168 and B. subtilis Marburg strain.

Bolotin A, Khazak V, Stoynova N, Ratmanova K, Yomantas Y, Kozlov Y.

Microbiology. 1995 Sep;141 ( Pt 9):2219-22.

PMID:
7496534
28.

Human RNA polymerase II subunit hsRPB7 functions in yeast and influences stress survival and cell morphology.

Khazak V, Sadhale PP, Woychik NA, Brent R, Golemis EA.

Mol Biol Cell. 1995 Jul;6(7):759-75.

29.

[A universal instinct for designing thermoregulated promotors in gram-positive bacteria].

Khazak VE, Veĭko VP, Sorokin AV.

Mol Biol (Mosk). 1991 Sep-Oct;25(5):1197-206. Russian.

PMID:
1836528
30.

[Expression unit in the region of replication initiation in the streptococcal plasmid pSM19035].

Sorokin AV, Khazak VE.

Mol Biol (Mosk). 1990 Jul-Aug;24(4):993-1000. Russian.

PMID:
2123523

Supplemental Content

Loading ...
Support Center